Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.
Also called NCT01955707
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 161 participants
- Sponsor
- Registry
-
NCT01955707
-
- Other papers using this trial's data
- Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01955707. Randomized; double masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2015-02 (actual). Results posted on 2016-07-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
- Acronym
- ACTION
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- natalizumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Biogen
Record details
- Record id
cardio:ct-nct01955707- Content hash
8a0d22281f70e1ce9c9d2ea5c16e2fe6777102ef7f27f492de5ec5f63f218d63